Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia (NUCLARA)
Status
Conditions
Treatments
Details and patient eligibility
About
Treatment of acute myeloid leukemia (AML) consists in two main phases: induction and consolidation. Standard chemotherapy combination for induction treatment associates cytarabine (AraC), a nucleoside analog, and an anthracycline (most often daunorubucin). About 60-70% of patients achieved complete remission after this standard chemotherapy. As cytarabine competes with endogenous nucleotides to exert its activity, the aim of this protocol is to study in vivo the effect of intracellular nucleotide pools on the efficacy of the induction treatment. Thus, intracellular nucleotides levels will be determined in peripheral blood mononuclear cells of patients with acute myeloid leukemia before treatment, and results will be compared with the efficacy of the treatment. This parameter will be assessed by the achievement of complete remission.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Patients Inclusion Criteria:
- age over 18 years
- acute myeloid leukemia
- standard induction chemotherapy with cytarabine and daunorubicin
- patients who received the information and did not object to participate to the study
Patients Exclusion Criteria:
- patients with acute myeloid leukemia 3
healthy volunteers Inclusion Criteria :
- adults without known hematological disease,
- adults who received the information and did not object to participate in the study
healthy volunteers Exclusion Criteria :
- Volunteers with known hematological disease.
Trial design
83 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal